| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.04 | 0.6 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | STF-62247 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |